AKRO News and Press, Akero Therapeutics Inc. From 06/30/20

SOUTH SAN FRANCISCO, Calif. , June 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced results of a 16-week analysis of secondary and exploratory endpoints in its Phase 2a BALANCED study of efruxifermin (EFX), formerly known as AKR-001, in patients with n...

Akero Therapeutics ( AKRO +2.4% ) plans to announce additional efficacy and safety data, including biopsy results, from its Phase 2a BALANCED study of AKR-001 in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH), on June 30 (after hours trading). More news on: Akero ...

SOUTH SAN FRANCISCO, Calif. , June 29, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that the company plans to discuss new efficacy and safety data, including biopsy results, from its Phase 2a BALANCED study of AKR-001 in patients with biopsy-confirmed nonal...

Akero Therapeutics ( AKRO +1.6% )  doses first subject in Cohort C, the expansion of its Phase 2a BALANCED trial , which will enroll 30 subjects who have non-alcoholic steatohepatitis (NASH) with compensated cirrhosis (F4), Child-Pugh Class A. More news on: Akero Therapeutics, Inc...

SOUTH SAN FRANCISCO, Calif. , June 17, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, ...

SOUTH SAN FRANCISCO, Calif. , June 10, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, ...

Plenty of promising biotech stocks on the market right now have slipped under the radar thanks to the COVID-19 pandemic. Akero Therapeutics (NASDAQ: AKRO) is one such company. Founded back in 2017 and only recently going public in mid-2019, Akero managed to attract a fair bit of excitement s...

Shares of TripAdvisor (NASDAQ: TRIP) were surging over 10% Monday morning as prospects for a reopened economy would have people traveling again, both in the U.S. and overseas. Stay-at-home orders in response to the coronavirus pandemic have crushed the travel and hospitality industries, but...

SOUTH SAN FRANCISCO, Calif., May 26, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NAS...

Akero Therapeutics (NASDAQ: AKRO ): Q1 GAAP EPS of -$0.42 beats by $0.19 . More news on: Akero Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...